Philip Marder

1.1k total citations
45 papers, 929 citations indexed

About

Philip Marder is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Philip Marder has authored 45 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Immunology and 10 papers in Oncology. Recurrent topics in Philip Marder's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Immune Response and Inflammation (9 papers) and Asthma and respiratory diseases (9 papers). Philip Marder is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Immune Response and Inflammation (9 papers) and Asthma and respiratory diseases (9 papers). Philip Marder collaborates with scholars based in United States, Netherlands and Singapore. Philip Marder's co-authors include Lisa J. Green, Stephen M. Spaethe, Christopher A. Slapak, Jon R. Schmidtke, Larry L. Froelich, Richard M. Schultz, Eric R. Prossnitz, Alexis Traynor‐Kaplan, L D Apelgren and Raymond F. Brown and has published in prestigious journals such as The Journal of Immunology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Philip Marder

45 papers receiving 889 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip Marder United States 17 418 265 237 101 98 45 929
Søren E. Bjørn Denmark 19 534 1.3× 147 0.6× 110 0.5× 50 0.5× 49 0.5× 37 1.4k
Deborah A. Rathjen Australia 17 352 0.8× 313 1.2× 73 0.3× 93 0.9× 76 0.8× 40 900
Kunio Nakahara Japan 19 533 1.3× 318 1.2× 165 0.7× 43 0.4× 71 0.7× 50 1.2k
Anne M. Pilaro United States 17 242 0.6× 359 1.4× 302 1.3× 111 1.1× 69 0.7× 26 1.1k
Doris Vokurková Czechia 17 326 0.8× 330 1.2× 195 0.8× 88 0.9× 78 0.8× 64 997
Cathy A. Farrell United States 11 375 0.9× 167 0.6× 108 0.5× 50 0.5× 152 1.6× 14 718
Nguyen T. Van United States 15 491 1.2× 93 0.4× 244 1.0× 174 1.7× 35 0.4× 24 924
Richard W. Leu United States 16 192 0.5× 448 1.7× 100 0.4× 76 0.8× 129 1.3× 48 840
Scott Thomson United Kingdom 11 482 1.2× 220 0.8× 100 0.4× 177 1.8× 71 0.7× 13 1.0k
Emmanuelle Rollet‐Labelle Canada 18 544 1.3× 386 1.5× 73 0.3× 87 0.9× 95 1.0× 27 1.0k

Countries citing papers authored by Philip Marder

Since Specialization
Citations

This map shows the geographic impact of Philip Marder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Marder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Marder more than expected).

Fields of papers citing papers by Philip Marder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Marder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Marder. The network helps show where Philip Marder may publish in the future.

Co-authorship network of co-authors of Philip Marder

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Marder. A scholar is included among the top collaborators of Philip Marder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Marder. Philip Marder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Litwin, Virginia & Philip Marder. (2011). Flow cytometry in drug discovery and development. Wiley eBooks. 4 indexed citations
2.
3.
Stanislaus, Dinesh, Xiaonan Yang, J. Liang, et al.. (2000). In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. Bone. 27(2). 209–218. 55 indexed citations
4.
Sofia, Michael J., Paul E. Floreancig, Stephen Baker, et al.. (1997). The Discovery of LY293111, a Novel, Potent and Orally Active Leukotriene B4 Receptor Antagonist of the Biphenylphenol Class. Advances in experimental medicine and biology. 400A. 381–386. 7 indexed citations
5.
Tonkinson, John L., Philip Marder, Sherri L. Andis, et al.. (1997). Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemotherapy and Pharmacology. 39(6). 521–531. 72 indexed citations
6.
Jong, E.M.G.J. de, P.E.J. van Erp, Malcolm I. Mitchell, et al.. (1997). The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111). Biochemical Pharmacology. 53(7). 1005–1012. 20 indexed citations
7.
Allen, David L., et al.. (1996). The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 341–349. 11 indexed citations
8.
Marder, Philip, et al.. (1996). Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist. British Journal of Clinical Pharmacology. 42(4). 457–464. 16 indexed citations
9.
10.
Vlahos, Chris J., William F. Matter, Raymond F. Brown, et al.. (1995). Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase.. The Journal of Immunology. 154(5). 2413–2422. 162 indexed citations
11.
12.
Sofia, Michael J., Paul E. Floreancig, Nicholas J. Bach, et al.. (1993). o-Phenylphenols: potent and orally active leukotriene B4 receptor antagonists. Journal of Medicinal Chemistry. 36(24). 3978–3981. 8 indexed citations
13.
Marder, Philip. (1993). Ligand Interactions with the RGD Recognition Site Alter Binding of GPIIb-IIIa Reactive Monoclonal Antibody to Human Platelets. Biochemical and Biophysical Research Communications. 195(2). 799–806. 2 indexed citations
14.
Marder, Philip, Richard M. Schultz, Stephen M. Spaethe, Michael J. Sofia, & David K. Herron. (1992). Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils. Prostaglandins Leukotrienes and Essential Fatty Acids. 46(4). 265–270. 16 indexed citations
15.
Schultz, Richard M., Philip Marder, Stephen M. Spaethe, David K. Herron, & Michael J. Sofia. (1991). Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production. Prostaglandins Leukotrienes and Essential Fatty Acids. 43(4). 267–271. 10 indexed citations
16.
17.
Bumol, Thomas F., et al.. (1988). Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal Antibody. Hybridoma. 7(4). 407–415. 56 indexed citations
18.
Zuckerman, Steven H., Robert D. Schreiber, & Philip Marder. (1988). Reactivation of class II antigen expression in murine macrophage hybrids.. The Journal of Immunology. 140(3). 978–983. 7 indexed citations
19.
Marder, Philip & Jon R. Schmidtke. (1985). Cyclosporin a inhibits helper/inducer surface antigen expression on activated human lymphocytes. International Journal of Immunopharmacology. 7(2). 165–175. 8 indexed citations
20.
Ades, Edwin W., et al.. (1984). Potentiation of Leu 11+ natural cytotoxicity by human interleukin 2. Clinical Immunology and Immunopathology. 32(1). 119–121. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Søren E. Bjørn Breakdown of academic impact, for papers by Deborah A. Rathjen Breakdown of academic impact, for papers by Kunio Nakahara Breakdown of academic impact, for papers by Anne M. Pilaro Breakdown of academic impact, for papers by Doris Vokurková Breakdown of academic impact, for papers by Cathy A. Farrell Breakdown of academic impact, for papers by Nguyen T. Van Breakdown of academic impact, for papers by Richard W. Leu Breakdown of academic impact, for papers by Scott Thomson Breakdown of academic impact, for papers by Emmanuelle Rollet‐Labelle
Rankless by CCL
2026